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Abstract 
Spontaneous neoplasm metastasis, a fatalist pathological feature of cancer, is a 
long-evolving, multi-steps process that can now only be treated or controlled by 
drugs or immuno-modulators. Probimane (Pro), as a representative of the well-
known class of antimetastatic agents 'Bisdioxopiperazine compounds (Biz)', is 
systematically studied for its absorption, distribution and excretion in mice 
bearing Lewis lung carcinoma by a radioactivity-detective method in this 
investigation. It is found that the 
14C-Pro concentrations in different normal 
organs of mice at 2 hrs are very high and dramatically declined at 24 and 48 
hrs. However, Pro concentrations in metastatic foci are slightly changed at the 
same time. Almost no change of Pro concentrations is observed in pulmonary 
metastatic nodules within 48 hrs. This evidence can be used to explain the 
characteristics of good metastatic inhibition by Biz compounds. The radioactivity 
in brain is relatively low because Pro can hardly penetrate into the blood-brain-
barrier to eliminate brain tumors. The excretion of 
14C-Pro is observed at the 
same ratios from both urine and feces and also at constant rates. These data 
are much useful for better understanding of the general pharmacological 
characters and possible antimetastatic mechanisms of actions of probimane 
and other Biz compounds from a new perspective and research angles. 
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Introduction 
There have been two most difficult problems in cancer biology and therapeutics, neoplasm 
metastasis and multi-drug-resistances (MDR). Among these two thorny problems, 
treatments of neoplasm metastasis are especially difficult and should be placed on higher 
agenda of the highest for its fatalist pathogenesis features and unpredictability of 
therapeutic outcome at the stage of drug initiation. Also, metastasized tumors often 
concomitantly manifest the characters of MDR. The treatment investigation of neoplasm 
metastases is one of the important topics for therapeutic researchers [1–3]. 
Bisdioxopiperazine compounds (Biz), including ICRF-154, Razoxane (ICRF-159, Raz), 
ICRF-186 and ICRF-187 (two stereo-isomers of Raz) and ICRF-193, developed in the UK, 
have been a series of serendipitous agents found to be effective against a model of 
spontaneous metastasis (Lewis lung carcinoma, 3LL) [4,  5]. Since Biz compounds are 
unique and conservative in pharmacological actions, their new analog Probimane 
[4,4'-(propane-1,2-diyl)bis[1-(morpholin-4-ylmethyl)piperazine-2,6-dione; AT-2153, Pro]   
[6–9] was synthesized at the Shanghai Institute of Materia Medica, Chinese Academy of 
Sciences, Shanghai, China. Since previous data showed that Pro has good 
antiproliferative effects in vitro [8] and moderate anticancer activity against the growth 
Lewis lung carcinoma in vivo [7], further work to specialized determinations of these 
characters is imperative and helpful to us. 
The researches of anti-metastatic drugs, though at the odds nowadays facing, will be the 
hottest spot and discipline in the future. This work should carefully study the fate of 
14C-probimane to help our understanding and knowledge about metastasis treatments of 
Biz compounds from drug distributions between normal organs, tumor tissues and 
metastatic foci.  
N
ON C
14
N
C
14
O
O
N
O NC
14
N
C
14
O
O
4,4'-(propane-1,2-diyl)bis[1-(morpholin-4-ylmethyl)(2,6-
14C2)piperazine-2,6-dione]
 
Fig. 1.  The structural formulae of 
14C-Probimane 
Materials and methods 
Drugs and Reagents: 
14C-Pro (Specific activity 130kBq.mg
-1) (Figure1) were prepared by 
Prof. Xin Zhang at the Department of Medicinal Chemistry, Shanghai Institute of Materia 
Medica, Chinese Academy of Science and suspended in normal saline before use.  
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Animals and Tumor Models: C57BL/6j strain mice were purchased from Shanghai Center 
of Laboratory Animal Breeding, Chinese Academy of Sciences and experimentations were 
conducted in compliance with the Guidelines for the Care and Use of Research Animals, 
NIH, established by the Washington University’s Animal Studies Committee.  
C57BL/6j mice (mean body weight 21.6g) were implanted sc with LLC (5×10
6 cells) from 
donor mice. 
14C-Pro 12mg was dissolved in 1 ml of normal saline at normal temperature. 
On day 17, mice were orally administered with 
14C-Pro 120mg/Kg (about 0.2ml drug per 
mouse) and all mice were unlimitedly given food and water during the whole experiment. 
All mice were collected for their urine and feces in specialized-tailored glassy cages 
containing bottom tube for urine collection and intermediate mesh for collecting feces and 
these mice were sacrificed 2, 24 and 48 hrs after the injection of 
14C-Pro. Then the blood 
(20µl), different organs of mice, primary tumors and pulmonary metastatic foci 
(approximately 3–10mg each – carefully weight and record organ weight) were separately 
collected in radioactive isotope couture. Exactly 0.1ml of formic acid and H2O2 were 
separately added to each testing-tube, then change in temperature up to 80°C for 45min 
for total digestion of tissues was observed. Then 5ml of ethylene glycol mono-ethyl/xylene 
mixture containing 0.5%PPO (5-phenyloxazolyl benzene) and 0.01%POPOP {1,4-bis-2-(5-
phenyloxazolyl)benzene} was added and radioactivity in the counter was detected by an 
auto-liquid-scintillate (YSJ-78) PR China.  
The radioactivity of urine and feces were also detected after 24 and 48hrs in the same 
way. This experiment was triplicated and all the data were statistically treated. 
Results 
The absorption and distribution of 
14C-probimane in mice:  
The distribution of 
14C-Pro in mice bearing Lewis lung carcinoma (3LL) is manifested in 
Table1. Table1 showed that the extents of 
14C-Pro in different normal organs of mice at 2 
hrs were very high and dramatically declined at 24 and 48 hrs. Only about 1/10 of Pro 
remained after 
14C-Pro was given at 48hrs comparing with those at 2hrs only except bowel 
and metastatic tumors. A persistent accumulation of Pro in metastatic tumors was 
observed. However the radioactivity in metastatic foci was slightly changed within 2 days. 
Almost no change in the Pro concentrations was observed in pulmonary metastatic 
nodules in the whole experiment and maintained in a high data within 48hrs. However, the 
radioactivity in primary tumors, though better than other normal tissues declined faster 
than metastatic tumors. The Pro ratios of metastatic tumor over primary tumor were 2.0, 
4.4 and 15.8 at 2, 24 and 48 hrs, respectively. This evidence is a useful piece of 
information for the explanation of high inhibitions against neoplasm metastases by Pro and 
other Biz compounds. In addition, the 
14C-Pro in brain was relatively low. It suggests that 
14C-Pro might hardly penetrate into the blood-brain-barrier to eliminate and kill brain 
tumors or metastasized tumors unto brains. The 
14C-Pro concentrations in gall bladders 
and intestines of mice at 2hrs are also very high. It suggests that 
14C-Pro is soluble in both 
aquatic and organic tissues of the bodies. The 
14C-Pro concentration in blood was declined 
very fast and only about 1% of 
14C-Pro maintained in blood after 48hrs compared with 
those in 2hrs.  
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Tab. 1.   Radioactivity distributions (Probimane concentrations) in different tissues of 
mice bearing Lewis lung carcinoma by ig 
14C-probimane 120mg/Kg 
Probimane concentrations (ng/g tissues)  Tissues 
2 hrs  24 hrs  48 hrs 
Brain    17.8  ±   2.0   9.7  ±   3.0    2.2  ±   1.0 
Skin    163.1 ± 10.9    67.2 ±   5.8    25.3 ±   1.7 
Muscle    122.6 ± 15.4    34.0 ±   3.1    15.0 ±   1.5 
Bone      90.1 ± 11.3    48.0 ±   7.3    15.1 ±   2.8 
Gall bladder    648.7 ± 59.9    92.7 ± 10.0    26.9 ±   2.3 
Primary  tumor    70.1  ±   5.6  24.1  ±   2.6    7.7  ±   1.1 
Metastatic tumor    142.3 ±   6.9  106.3 ±   7.0  121.5 ±   9.7 
Heart    124.7 ± 13.6    22.8 ±   1.9      7.2 ±   0.7 
Lung    149.5 ± 12.2    38.5 ±   2.9    29.2 ±   3.2 
Testis    444.5 ± 25.0    46.5 ±   3.6    20.0 ±   2.5 
Liver    370.6 ± 26.7    39.0 ±   4.7    15.3 ±   3.3 
Spleen    365.3 ± 16.4    22.4 ±   2.3    15.9 ±   4.1 
Kidney    446.8 ± 32.5  117.4 ±   9.9    22.7 ±   2.0 
Stomach  1155.3 ± 45.7  107.2 ± 12.3    20.1 ±   2.5 
Bowel    261.8 ± 17.4    60.1 ±   4.7  122.3 ± 14.6 
Blood    202.4 ± 15.7    27.6 ±   2.0      3.3 ±   0.5 
 
The excretion of 
14C-Pro: 
The excretion of 
14C-Pro was almost at the same ratios from urine and feces and in 
constant rates within the whole experiment Table2. It is a useful excretive data for us to 
understand the general characteristics and functions of Pro in living-bodies. 
Tab. 2.   The radioactivity excretion from mice bearing Lewis lung carcinoma by ig 
14C-probimane 120mg/Kg 
Excretion (%)  Time (hrs) 
Urine Feces  Total 
24  18.7 ± 1.7  16.5 ± 1.5  35.2 ± 3.0 
48  33.9 ± 2.5  32.0 ± 2.8  65.9 ± 4.4 
 
Discussion  
Since tumor metastasis is responsible for more than 60% of cancer deaths worldwide, 
metastasis therapy, as a result, remains to be one of the biggest challenges among all 
cancer therapeutics researches. Biz compounds are well-known for their antimetastasis 
action and several of their putative mechanisms [10–14]. However, their new modes of 
action and therapeutic profiles remain to be investigated for further understanding and 
proposition for their potential clinical availability. This work is a typical one. The inhibition of 
neoplasm metastasis by Raz has been previously explained as a result of reduction in the 
formation of blood vessels in primary tumor tissues (neovasculature) [10–12]. Thus, it has 
been proposed that Raz remains ineffective against the pulmonary metastases of 3LL 
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(formed metastatic foci) [15] and nevertheless Pro can be more effective in the inhibition of 
neoplasm metastasis than Raz in formed metastatic foci through stronger antiproliferative 
effect [8, 9] and drug accumulation. From this data of 
14C-Pro tracing, an obvious greater 
accumulation of Pro was found in tumor tissues, especially in metastatic foci. It can help to 
explain why Pro might effectively inhibit pulmonary metastases of Lewis lung carcinoma by 
its higher accumulation and affinity to metastatic nodules which lead further into higher 
cytotoxicity against formed metastatic foci in living-bodies.  
This work shows that Pro can hardly penetrate into the blood-brain-barrier, and it suggests 
Pro might be less effective to brain tumors or against those other tumors which have been 
metastasized into the brains. This result is very similar with previously reported data of 
Raz by Greig N et al determined by a HPLC assay [16]. 
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